Sangamo Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
16/02/2024 22:36
* Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected
to show
a fall in quarterly revenue when it reports results on February
20 (estimated) for the period ending December 31 2023
* The Richmond California California-based company is
expected to
report a 70.2% decrease in revenue to $8.105 million from $27.23
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sangamo Therapeutics Inc
is
for a loss of 26 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sangamo
Therapeutics Inc is $2.00, above its last closing price
of $1.05.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.31 -0.32 -0.59 Missed -84.4
Jun. 30 2023 -0.35 -0.34 -0.66 Missed -92.7
Mar. 31 2023 -0.32 -0.33 0.12 Beat 136.6
Dec. 31 2022 -0.35 -0.36 -0.32 Beat 11.1
Sep. -0.34 -0.36 -0.34 Beat 4.3
30 2022
Jun. 30 2022 -0.33 -0.35 -0.29 Beat 17.8
Mar. 31 2022 -0.31 -0.31 -0.30 Beat 3.5
Dec. 31 2021 -0.35 -0.35 -0.26 Beat 24.7
This summary was machine generated February 16 at 22:36 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)